The American Journal of Managed Care

Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

Tildrakizumab showed sustained efficacy in plaque psoriasis, with nearly three years of mean drug survival across BSA severities and obesity categories. Patients experienced significant improvements ...
Medscape

Anti-IL-17, Anti-IL-23 Therapies Show Sustained Psoriasis Control

SAN DIEGO — In published trials, both an IL-17 inhibitor and an IL-23 inhibitor achieved impressive rates of clear or almost clear responses in patients with moderate to severe plaque psoriasis, but ...
The American Journal of Managed Care

Simplified Psoriasis Severity Measure Shows Strong Correlation With PASI

G2-PASE approximates PASI using routinely captured PGA and BSA, aiming to replace impractical PASI scoring in real-world clinical settings without sacrificing measurement fidelity. Strong performance ...
Medscape

For Moderate-to-Severe Psoriasis, Novel Oral Therapy Acts Like a Biologic in Phase 3 Trial

Icotrokinra, a novel oral interleukin (IL)-23 inhibitor, provided a level of response in moderate-to-severe plaque psoriasis that is similar to that previously reported with injectable biologics, ...